The purpose of this project is to determine the reliability and validity of an instrument designed to assess functional ability of patients with Alzheimer's Disease (AD) enrolled in clinical treatment trials. At present functional scales measuring activities of daily living (ADLs) are often used as secondary but rarely as primary outcome measures either in trials of antidementia drugs or in trials of drugs for the treatment of ancillary symptoms such as agitation. Existing instruments are limited first because there is no consensus that they measure all of the major functional limitations found in AD patients and more importantly, that no existing instrument has been shown to be suitable for assessing functional change over a broad spectrum of dementia severity. Previously we have conducted reliability and longitudinal validity studies of the two most widely used instruments for assessing activities of daily living (ADLs) in AD patients, the Physical and Self-Maintenance Scale (PSMS) and Instrumental Activities of Daily Living Scale (IADLS) of Lawton and Brodie (1969). These studies have determined that many but not all of the items on these two scales have adequate reliability and longitudinal validity. We propose to modify some of the PSMS items to enhance reliability and to modify or replace several IADLS items so that they are less gender and location specific. Then we propose to assess the inter-rater, test-retest and alternate source reliability of each item; those with poor reliability will be eliminated or modified. Then a group of at least 50 AD patients with a wide range of baseline severity will be evaluated every six months for a minimum of 12 months. The ability of each item to measure longitudinal change for each level of dementia severity will be determined, and the reliability and sensitivity of the scale will be compared with other clinician rating scales used in clinical trials. The ultimate aim of the project is to produce an instrument for measuring activities of daily living (ADLs) in AD patients that can be used to evaluate the efficacy of drug treatments or other interventions.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
2P50AG005138-11
Application #
3745754
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
11
Fiscal Year
1994
Total Cost
Indirect Cost
Name
Mount Sinai School of Medicine
Department
Type
DUNS #
City
New York
State
NY
Country
United States
Zip Code
10029
Barnes, Josephine; Bartlett, Jonathan W; Wolk, David A et al. (2018) Disease Course Varies According to Age and Symptom Length in Alzheimer's Disease. J Alzheimers Dis 64:631-642
Gandal, Michael J; Haney, Jillian R; Parikshak, Neelroop N et al. (2018) Shared molecular neuropathology across major psychiatric disorders parallels polygenic overlap. Science 359:693-697
Huckins, L M; Hatzikotoulas, K; Southam, L et al. (2018) Investigation of common, low-frequency and rare genome-wide variation in anorexia nervosa. Mol Psychiatry 23:1169-1180
Schaffert, Jeff; LoBue, Christian; White, Charles L et al. (2018) Traumatic brain injury history is associated with an earlier age of dementia onset in autopsy-confirmed Alzheimer's disease. Neuropsychology 32:410-416
Ki?emet-Piska?, Spomenka; Babi? Leko, Mirjana; Blažekovi?, Antonela et al. (2018) Evaluation of cerebrospinal fluid phosphorylated tau231 as a biomarker in the differential diagnosis of Alzheimer's disease and vascular dementia. CNS Neurosci Ther 24:734-740
Soleimani, Laili; Ravona-Springer, Ramit; Heymann, Anthony et al. (2018) Depression is more strongly associated with cognition in elderly women than men with type 2 diabetes. Int Psychogeriatr :1-5
Burke, Shanna L; Maramaldi, Peter; Cadet, Tamara et al. (2018) Decreasing hazards of Alzheimer's disease with the use of antidepressants: mitigating the risk of depression and apolipoprotein E. Int J Geriatr Psychiatry 33:200-211
Audrain, Mickael; Haure-Mirande, Jean-Vianney; Wang, Minghui et al. (2018) Integrative approach to sporadic Alzheimer's disease: deficiency of TYROBP in a tauopathy mouse model reduces C1q and normalizes clinical phenotype while increasing spread and state of phosphorylation of tau. Mol Psychiatry :
Boban, Mirta; Babi? Leko, Mirjana; Miški?, Terezija et al. (2018) Human neuroblastoma SH-SY5Y cells treated with okadaic acid express phosphorylated high molecular weight tau-immunoreactive protein species. J Neurosci Methods :
Zhu, Carolyn W; Grossman, Hillel; Neugroschl, Judith et al. (2018) A randomized, double-blind, placebo-controlled trial of resveratrol with glucose and malate (RGM) to slow the progression of Alzheimer's disease: A pilot study. Alzheimers Dement (N Y) 4:609-616

Showing the most recent 10 out of 555 publications